Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
В этом разделе статьи показаны на английском.
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Редакция Trade News (2026-10-02) фиксирует рынок: Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes. Первоисточник — оригинал CNBC Top News (cnbc.com).